Advertisement

Topics

Novartis anti-inflammatory drug locks down landmark results in CV study

05:24 EDT 22 Jun 2017 | BioPharmaDive

A six-year Phase 3 study showed Ilaris reduced the risk of cardiovascular events, a surprise result which buoys the Swiss pharma's heart drug portfolio.

Original Article: Novartis anti-inflammatory drug locks down landmark results in CV study

NEXT ARTICLE

More From BioPortfolio on "Novartis anti-inflammatory drug locks down landmark results in CV study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...